MS and Demyelinating Disorders

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Results from a prospective study demonstrated a higher visual field defect in patients with neuromyelitis optica spectrum disorder-optic neuritis compared with those who had idiopathic optic neuritis.

Here's some of what is coming soon to NeurologyLive® this week.

Over a 12-week trial, females with MS on bupropion demonstrated improvements in sexual satisfaction, sexual desire, vaginal moisture, and orgasm intensity.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in multiple sclerosis in 2022.

In 2022, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.

Marketed as Briumvi, the TG Therapeutics treatment becomes the third anti-CD20 agent approved for relapsing multiple sclerosis and is expected to become available in the first quarter of 2023.

These were the most-watched interviews with experts in multiple sclerosis that we conducted in 2022, brought to you as part of NeurologyLive®'s Year in Review.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.

A panel of experts discuss COVID-19 vaccine efficacy for patients undergoing treatment for multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 24, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 23, 2022.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2022.

Clinician perceived cognitive performance was significantly predicted by multiple factors, including cognitive scores, physical disability, age, and depression.

The neuropsychologist at Rutgers University, in New Brunswick, New Jersey, spoke about the different types of nonpharmacological digital interventions for multiple sclerosis. [WATCH TIME: 4 minutes]

A review of randomized controlled trials on balance interventions highlighted the effects for improved mobility and balance in multiple sclerosis.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read question-and-answer interviews we've conducted with experts in various neurology specialties in 2022.

An expert panel considers patients with multiple sclerosis who may need to discontinue treatment during pregnancy.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review data on short-term interruption of ponesimod vs teriflunomide when treating multiple sclerosis.

The director of the Mellen Center for MS at Cleveland Clinic offered an overview of the State of the Science Summit that was held on November 10, 2022, featuring a panel of expert clinicians. [WATCH TIME: 4 minutes]

Using a cohort of more than 2500 patients with MS on disease-modifying therapies, treatment initiation within the first 2 years of disease onset was more beneficial on patient-reported outcomes than 2-4 years postonset.

Here's some of what is coming soon to NeurologyLive® this week.

Chaired by Robert Bermel, MD, of Cleveland Clinic, the presentations also feature Jeffrey Cohen, MD; Amy Kunchock, MBBS, MMed; and Brandon Moss, MD. [WATCH TIME: 1 hour, 30 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.